News stories about VistaGen Therapeutics (NASDAQ:VTGN) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VistaGen Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8295582517061 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of VistaGen Therapeutics (NASDAQ:VTGN) traded up $0.02 on Friday, hitting $1.22. The company’s stock had a trading volume of 873,500 shares, compared to its average volume of 1,686,813. The company has a debt-to-equity ratio of -0.01, a quick ratio of 1.23 and a current ratio of 1.23. VistaGen Therapeutics has a 52-week low of $0.69 and a 52-week high of $3.90. The company has a market capitalization of $25.78, a price-to-earnings ratio of -0.82 and a beta of -1.23.
VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 9th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). equities analysts forecast that VistaGen Therapeutics will post -1.99 EPS for the current year.
VistaGen Therapeutics Company Profile
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.